Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.

[1]  M. Zabel,et al.  Characterisation of thyroid medullary carcinoma TT cell line. , 1997, Histology and histopathology.

[2]  R. Udelsman,et al.  Management of thyroid cancer. , 2001, Annali italiani di chirurgia.

[3]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[4]  Xin Chen,et al.  Performance of Similarity Measures in 2D Fragment-Based Similarity Searching: Comparison of Structural Descriptors and Similarity Coefficients , 2002, J. Chem. Inf. Comput. Sci..

[5]  A. Ryan,et al.  Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors , 2004, Oncogene.

[6]  William Pao,et al.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Z. Werb,et al.  PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival , 2005, Nature Cell Biology.

[8]  N. Meanwell,et al.  A base-catalyzed, direct synthesis of 3,5-disubstituted 1,2,4-triazoles from nitriles and hydrazides , 2005 .

[9]  Svend Kjær,et al.  Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* , 2006, Journal of Biological Chemistry.

[10]  C. Strock,et al.  Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[11]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[12]  Sanjivanjit K. Bhal,et al.  The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. , 2007, Molecular pharmaceutics.

[13]  Jürgen Bajorath,et al.  Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. , 2007, Drug discovery today.

[14]  G. G. Dubinina,et al.  In silico design of protein kinase inhibitors: successes and failures. , 2007, Anti-cancer agents in medicinal chemistry.

[15]  P. Miccoli,et al.  Dedifferentiated thyroid cancer: a therapeutic challenge. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  S. Moore.  Molecular targets in medullary thyroid carcinoma , 2008 .

[17]  M. Yeh,et al.  Inherited endocrinopathies: an update. , 2008, Molecular genetics and metabolism.

[18]  A. Pinchera,et al.  Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[19]  George Karypis,et al.  Indirect Similarity Based Methods for Effective Scaffold-Hopping in Chemical Compounds , 2008, J. Chem. Inf. Model..

[20]  E. Ferrannini,et al.  Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. , 2008, European journal of endocrinology.

[21]  E. Ferrannini,et al.  Primary cell cultures from anaplastic thyroid cancer obtained by fine‐needle aspiration used for chemosensitivity tests , 2008, Clinical endocrinology.

[22]  Giampietro Gasparini,et al.  Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications , 2008, Nature Clinical Practice Oncology.

[23]  F. Zunino,et al.  Targeting RET for thyroid cancer therapy. , 2009, Biochemical pharmacology.

[24]  Gennady Verkhivker,et al.  Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. , 2009, Biophysical journal.

[25]  F. Da Settimo,et al.  Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies. , 2009, Journal of medicinal chemistry.

[26]  M. Shah,et al.  Targeting RET Receptor Tyrosine Kinase Activation in Cancer , 2010, Clinical Cancer Research.

[27]  J. Murray-Rust,et al.  Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. , 2010, Bioorganic & medicinal chemistry.

[28]  M. Pelizzo,et al.  Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT , 2011, BMC Cancer.

[29]  G. Alí,et al.  Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer , 2011 .

[30]  Raimund Mannhold,et al.  QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability. , 2012, Molecular pharmaceutics.

[31]  N. Chau,et al.  Vandetanib for the Treatment of Medullary Thyroid Cancer , 2012, Clinical Cancer Research.

[32]  M. Sugawara,et al.  Medullary Thyroid Cancer—Current Treatment Strategy, Novel Therapies and Perspectives for the Future , 2012, Hormones and Cancer.

[33]  F. Kraeber-Bodéré,et al.  Treatment of metastatic medullary thyroid cancer with vandetanib: need to stratify patients on basis of calcitonin doubling time. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Novellino,et al.  Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. , 2012, Journal of medicinal chemistry.

[35]  E. Kebebew,et al.  Diagnosis of thyroid cancer: state of art. , 2013, Expert opinion on medical diagnostics.

[36]  E. Novellino,et al.  Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors. , 2013, Journal of medicinal chemistry.

[37]  Alessandro Antonelli,et al.  Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma , 2013, International journal of endocrinology.

[38]  M. Borrello,et al.  RET inhibition: implications in cancer therapy , 2013, Expert opinion on therapeutic targets.

[39]  F. Da Settimo,et al.  Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). , 2013, European journal of medicinal chemistry.

[40]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Erin F. Simonds,et al.  Drugging MYCN through an allosteric transition in Aurora kinase A. , 2014, Cancer cell.

[42]  E. Novellino,et al.  Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies. , 2014, Journal of medicinal chemistry.

[43]  Johannes C. Hermann,et al.  Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines. , 2014, Bioorganic & medicinal chemistry letters.

[44]  Nathan Brown,et al.  Best of Both Worlds: On the Complementarity of Ligand-Based and Structure-Based Virtual Screening , 2014, J. Chem. Inf. Model..

[45]  Weilin Wu,et al.  Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors. , 2015, Journal of medicinal chemistry.

[46]  J. Edwards,et al.  A Prospective Virtual Screening Study: Enriching Hit Rates and Designing Focus Libraries To Find Inhibitors of PI3Kδ and PI3Kγ. , 2016, Journal of medicinal chemistry.

[47]  C. La Motta,et al.  Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells , 2017, Medicinal research reviews.